A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 As Monotherapy In Subjects With Mature B-Cell Malignancies

Clinical Trial Details

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

SGR-1505 is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA).

In this study, SGR-1505 will be taken orally either once daily or every 12 hours.

Participation in this research will last about 6-7 months, depending on how well participants tolerate the study drug and whether their disease returns or not. Participation could be longer or shorter than 6-7 months.

Key Eligibility:

Open to men and women above the age of 18 who have been diagnosed with a mature B-cell malignancy
Participants must not have received prior treatment with standard radiotherapy, cytotoxic chemotherapy, anti-cancer treatments, or other investigational agents within 4 weeks of first dose of study treatment

Detailed eligibility will be reviewed when you contact the study team.

Return to List